Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended September 2023, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $3.85 billion, up 7.1% over the same period last year. EPS came in at $0.60, compared to $0.59 in the year-ago quarter.
The reported revenue represents a surprise of +4.00% over the Zacks Consensus Estimate of $3.7 billion. With the consensus EPS estimate being $0.60, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- International Markets: $485 million compared to the $469.36 million average estimate based on four analysts. The reported number represents a change of +2.1% year over year.
Geographic Revenue- North America: $2 billion compared to the $1.84 billion average estimate based on four analysts. The reported number represents a change of +10.7% year over year.
Geographic Revenue- North America- COPAXONE: $103 million compared to the $67.49 million average estimate based on four analysts. The reported number represents a change of -1.9% year over year.
Geographic Revenue- North America- BENDEKA / TREANDA: $57 million versus the four-analyst average estimate of $53.46 million. The reported number represents a year-over-year change of -26%.
Geographic Revenue- North America- AUSTEDO: $339 million compared to the $316.67 million average estimate based on four analysts. The reported number represents a change of +30.4% year over year.
Geographic Revenue- North America- Anda: $367 million versus $368.52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change.
Geographic Revenue- Europe- COPAXONE: $55 million versus the four-analyst average estimate of $49.90 million. The reported number represents a year-over-year change of -12.7%.
Geographic Revenue- Europe- Respiratory products: $61 million versus $63.20 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
Geographic Revenue- International Markets- Generic products: $381 million versus $386.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.1% change.
Revenue- Other- Total: $332 million versus the two-analyst average estimate of $172.69 million. The reported number represents a year-over-year change of +6.8%.
Revenue- API sales to third parties: $131 million versus the two-analyst average estimate of $146.85 million. The reported number represents a year-over-year change of -12.1%.
Revenue- COPAXONE- Total: $168 million compared to the $130.84 million average estimate based on two analysts. The reported number represents a change of -5.1% year over year.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>
Shares of Teva Pharmaceutical Industries Ltd. have returned -2.3% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
